Company profile
Revolution Medicines, Inc.
NASDAQ: RVMD · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
53DFH 52DQ 62GM 27SS 72
v0.1 · 65/100 weight · provisional
↑ market scale, Altman-Z · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.1B
Employees
883
as of 2026-08-04
Market cap
$38.8B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$1.1B-$1.1B2025
Operating income-$1.2B-$1.2B2025
Total assets$2.4B$2.4B2025
Liabilities$723.2M$723.2M2025
Equity$1.6B$1.6B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Collaboration Revenue Member100%
By geography
Not disclosed.
The read
What is Revolution Medicines, Inc.’s revenue?
Revolution Medicines, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
GlobeStar Therapeutics Corporation——VMS Rehab Systems, Inc.——Goldenwell Biotech, Inc.16DSummit Therapeutics Inc.49DSpyre Therapeutics, Inc.64CPraxis Precision Medicines, Inc.61CNeighbors
San Mateo →Key facts
CEOMark A. Goldsmith
SectorHealthcare
IndustryBiotechnology
HeadquartersRedwood City, CA
ExchangeNASDAQ: RVMD
Employees883
IPO date2020-02-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.